Inclusion Criteria:  Confirmed MDS, IPSS low / intermediate risk-1 In the 4 weeks before inclusion, the average value of platelets was ≤ 30 × 10e9 / L, or < 50 × 10e9 / L with bleeding events Patients with EPO due to anemia and G-CSF due to severe neutropenia can be included, and the dosage will not change during trial ECOG 0-2 points Able to sign informed consent  Exclusion Criteria:  Pregnant or lactating IPSS intermediate risk-2 / high risk MDS More than 5% of myeloblasts in bone marrow Myelofibrosis Previous transplantation or ATG treatment within 6 months Previous use of TPO or other TPO receptor agonists Active infection or tumor Thromboembolic or hemorrhagic disease Serious heart disease, including unstable angina, congestive heart failure, arrhythmia, 1-year history of myocardial infarction Baseline liver and kidney function: ALT / ASL over than 3 times normal upper limit, TBIL over than 2 times normal upper limit, and creatinine over than 2 times normal upper limit